Related Experiment Video
Updated: Jul 20, 2026
11:13
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Cytokines in breast cancer
1Department of Internal Medicine, University of Pisa, Via Roma 67, 56126 Pisa, Italy. a.nicolini@int.med.unipi.it
Cytokine & Growth Factor Reviews
|August 26, 2006
Summary
Cytokines play a dual role in breast cancer, with some promoting growth and others inhibiting it. Certain cytokine therapies show promise for patients with minimal residual or controlled disseminated disease.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cytokines are crucial signaling molecules involved in breast cancer progression and metastasis.
- Specific cytokines like interleukins (ILs) and interferons (IFNs) have identified roles in tumor microenvironments and metastatic sites.
- The prognostic significance of circulating cytokine levels varies, with some indicating favorable outcomes and others unfavorable.
Purpose of the Study:
- To review the multifaceted roles of cytokines in breast cancer.
- To examine the therapeutic applications of cytokines in advanced breast cancer treatment.
- To evaluate the clinical efficacy of cytokine-based therapies, particularly Interleukin-2 (IL-2) and Interferon-beta (IFNbeta).
Main Methods:
- Literature review of cytokine roles in breast cancer.
- Analysis of signaling pathways involving IL-1 family, IL-6, IL-11, IL-18, IFNs, IRF-1, and IRF-2.
- Evaluation of clinical trial data for cytokine therapies in advanced breast cancer.
Main Results:
- Certain cytokines (e.g., IL-1, IL-6) stimulate breast cancer growth, while others (e.g., IL-12, IFNs) inhibit it.
- Circulating levels of specific cytokines serve as prognostic indicators.
- While many cytokine therapies yielded disappointing results, pilot studies suggest IL-2 and IFNbeta may benefit patients with minimal residual or controlled disseminated disease.
Conclusions:
- Cytokines exhibit complex and often opposing effects on breast cancer.
- Cytokine-based therapies, particularly IL-2 and IFNbeta, warrant further investigation for specific patient populations.
- Optimized application of IL-2 and IFNbeta may improve clinical benefit and survival in select advanced breast cancer cases.
More Related Videos
06:36A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion
Published on: April 24, 2015
09:01Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...